Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Esophageal Neoplasms 2Neoplasms 1Neoplasm Recurrence, Local 1Neoplasm Metastasis 1Esophageal Squamous Cell Carcinoma 1Endometrial Neoplasms 1

Interventions

pembrolizumab 26Paclitaxel 25Carboplatin 19Bevacizumab 14Specimen Handling 11Magnetic Resonance Spectroscopy 9Doxorubicin 8Cisplatin 8Taxes 7Biopsy 7olaparib 6lenvatinib 6Megestrol Acetate 6Letrozole 6Fulvestrant 6durvalumab 5dostarlimab 5Nivolumab 5Medroxyprogesterone Acetate 5Gemcitabine 5Docetaxel 5trastuzumab deruxtecan 4Trastuzumab 4Tirzepatide 4Progestins 4Fluorouracil 4palbociclib 3ipatasertib 3atezolizumab 3abemaciclib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Endometrial Neoplasms × TP protocol × 90 days × Clear all
NCT06532539 2026-04-24

Cadonilimab With Chemoradiation for Recurrent and Oligometastatic Endometrial Carcinoma

Shandong Cancer Hospital and Institute

Phase 2 Recruiting
30 enrolled
Gynecologic

Neoplasm Metastasis, Neoplasm Recurrence, Local, Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡